BridgeBio Oncology Therapeutics (BBOT) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BridgeBio Oncology Therapeutics is the larger company by market cap ($274.2 million vs $259.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | VOGX |
|---|---|---|
| Share price | $3.42 | $17.49 |
| Market cap | $274.20M | $259.82M |
| 1-day change | -0.58% | +8.23% |
| YTD return | -72.68% | — |
| 1-year return | -71.56% | — |
| EPS (TTM) | $-0.07 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $38.41 |
| 52-week low | $3.27 | $12.95 |
| Distance from 52-week high | -77.00% | -54.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +617.84% | +214.47% |
| Average volume | 468.83K | 188.79K |
| Shares outstanding | 80.17M | 14.86M |
| Employees | 88 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
BBOT vs VOGX FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Vogenx?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $274.20M compared with $259.82M for Vogenx (VOGX).
Are BridgeBio Oncology Therapeutics and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.